BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced the U ...
BOSTON--(BUSINESS WIRE)-- Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced ...
-- STAR-0310 Exhibits Longest-in-Class Half-Life of 68 Days and Cytokine Suppression Lasting At Least 20 Weeks After a Single 300 mg SC Injection, Supporting Potential Every-Six-Month Administration - ...
Please provide your email address to receive an email when new articles are posted on . Tremfya (guselkumab) is an interleukin-23 inhibitor. The submissions are supported by clinical and ...
BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today announced ...
BOSTON - Astria Therapeutics, Inc. (NASDAQ:ATXS) will present initial data from the Phase 1a trial of its investigational drug STAR-0310 at the European Academy of Dermatology & Venereology (EADV) ...
Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced positive initial results from ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results